Brief Communication

SP600125, a selective JNK inhibitor, is a potent inhibitor of NAD(P)H: quinone oxidoreductase 1 (NQO1)

Bing-ling Zhong1, Yi-fei Zhang1, Hao-yi Zheng1, Qiang Chen2,3, Hua-dong Lu4, Xiu-ping Chen1,2,3
1 State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China
2 Faculty of Health Sciences, University of Macau, Macao, China
3 MoE Frontiers Science Center for Precision Oncology, University of Macau, Macao, China
4 Department of Pathology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen Clinical Research Center for Cancer Therapy, Xiamen 361015, China
Correspondence to: Hua-dong Lu: 13606913781@139.com, Xiu-ping Chen: xpchen@um.edu.mo,
DOI: 10.1038/s41401-024-01418-1
Received: 30 April 2024
Accepted: 25 October 2024
Advance online: 25 November 2024

Abstract

The c-Jun N-terminal kinases (JNKs) has been identified as a critical modulator in multiple cellular processes, including stress stimulus, inflammation, cell proliferation, apoptosis, etc. SP600125 is a widely used ATP-competitive reversible JNKs inhibitor. NAD(P)H: quinone oxidoreductase 1 (NQO1) is a flavoprotein mediated two or four electron-reduction of quinones. Here, we showed that SP600125 bind to the active pocket of NQO1 and inhibit NQO1 activity. SP600125 exhibits comparable inhibitory effects on NQO1-mediated quinone bioactivation, H2O2 generation, and cell death, as the specific NQO1 inhibitor dicoumarol (DIC). Importantly, the inhibitory effects of SP600125 on NQO1 are independent of JNKs inhibition. These results suggested that SP600125 is a novel NQO1 inhibitor, which provides new insights into the mechanism of action of SP600125. Furthermore, SP600125 should be used more cautiously as a JNKs inhibitor, especially when NQO1 is highly expressed.

Keywords: SP600125; JNK; NQO1

Article Options

Download Citation

Cited times in Scopus